Steven Wolf, MD Email Steven Wolf
- ASSOCIATE PROFESSOR | Neurology
- ASSOCIATE PROFESSOR | Pediatrics
- Pediatric Neurology
- Hospital Affiliations
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
Book an Appointment - Steven Wolf, MD
Steven M. Wolf, MD is Associate Professor of Neurology and Director of Pediatric Epilepsy and Co-Director of the Level 4 Comprehensive Epilepsy Center at Mount Sinai, positions that he has held since 2000. He is well-recognized as an epilepsy authority. He received his medical degree at the Albany Medical Center. He trained in pediatrics, child neurology, and epilepsy at the Albert Einstein College of Medicine in the Bronx. He is board certified in pediatrics, epilepsy, clinical neurophysiology, and neurology with special recognition in child neurology.
Steve Wolf, MD and Patty McGoldrick, NP work together in a unique collaborative practice.Together, they direct the Comprehensive Pediatric Epilepsy Center, the Developmental Disability Center at Mount Sinai West and the Tuberous Sclerosis Center at Mount Sinai. They have written and published numerous peer–reviewed articles and guides for patients and families while caring for patients and teaching students and residents. They participate in original research, and publish on many aspects of epilepsy including novel treatments, outcomes, epilepsy surgery, and genetics with the scientists at the Friedman Brain Institute.
They are committed to helping people with epilepsy and their families by recognizing behavioral and school issues and addressing the co-morbidities of epilepsy including headaches, learning disabilities and attention deficit disorders. They have been honored for their work with people with epilepsy and developmental disabilities and serve on the boards of several organizations. Dr. Steven Wolf and Dr. Patricia McGoldrick conduct all of their clinical research with Dr. Harriet Kang.
American Board of Psychiatry and Neurology, Epilepsy
Child Neurology, American Board of Psychiatry and Neurology
- Anoxic Brain Damage
- Arnold-Chiari Syndrome
- Bell's Palsy
- Brain Malformation
- Cerebral Palsy
- Chronic Daily Headache
- Chronic Migraine
- Electroencephalogram (EEG)
- Electroencephalogram (EEG) with video
- Evoked Potentials
- Lumbar Puncture
- Mental Development Evaluation
- Seizure Disorder
- Vagal nerve stimulator (VNS) for epilepsy
MD, Albany Medical Center
Montefiore Medical Center
Fellowship, Pediatric Neurology
Montefiore Medical Center
Montefiore Medical Center
Epilepsy Foundation Greater New York
Honored with Patricia McGoldrick NP
Excellence of Care
Ferncliff Manor Children’s Center Award
Zella Bronfman Award
For innovative services to the disabled
Volunteer of the Year
Epilepsy Foundation NYC
Volunteer of the Year
Ferncliff Home for Children - SAIL at Ferncliff
New York Magazine
New York Family Magazine
A 12-Month, Open-Label, Repeat-Dose Safety Study of NRL-1 In Epilepsy Subjects This is an open-label study to evaluate diazepam administered into the nose for one year in subjects ages 6-65 experiencing seizure emergencies including acute repetitive seizures (ARS). ARS is definied as intermittent increases of seizure activity while on a stable regimen of antiepileptic drugs (AEDs). Diazepam given intravenously (i.e., through a vein) has been used for over 30 years for the treatment of seizure emergencies, however a rectal gel formulation of diazepam called Diastat is the current standard of care. Diastat is the only diazepam formulation that is approved in the US for ARS. Due to the route of administration, the use of Diastat has been limited primarily to children ages 2-12 years. The study product, NRL-1 was previously studied in health adults and based on the results, it is estimated that diazepam exposure from the intranasal administration will be comparable to that seen in the rectal gel, but will present a more convenient route of administration for patients and caregivers.
PReventing Epilepsy using Vigabatrin in iNfants with Tuberous sclerosis complex
The study design is a Phase IIb prospective multi-center, randomized, placebo-controlled, double-blind clinical trial. The goal will be to enroll 80 infants with TSC who are less than 6 months of age prior to the onset of their first seizure. There are two hypotheses, (1) prophylactic treatment with Vigabatrin will prevent drug-resistant epilepsy in patients with TSC, and (2) Video EEG biomarkers can be found to help identify patients at risk of developing drug-resistant epilepsy.
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects with Epilepsy. Acute repetitive seizures (ARS) including break through seizures, repetitive seizures, and seizure clusters occur in a significant number of epilepsy patients who are on established antiepileptic drug treatment. The only FDA approved treatment for ARS is Diastat Rectal Gel, a formulation of diazepam that must be administered rectally. There is a need for diazepam that can be more easily administered at home and at school for patients with ARS. This study is a phase 3 study looking at the long-term safety and tolerability of a novel route of administration of diazepam for ARS. The study drug is a soluble film that is placed inside the cheek of the subjects during ARS.
A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults with LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults with LGS This is a two part study of an investigation antiepileptic drug, fenfluramine hydrochloride (ZX008), for the adjunctive treatment of seizures in children and adults with Lennox Gastaut Syndrome. Part one of the study is a randomized, placebo controlled, double blind trial which will last for one year, and the second part is an open label safety extension which will also last for one year.
A Multicenter, Open Label Crossover Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Pediatric Subjects with Epilepsy. Diazepam is commonly used to treat a range of conditions, including seizures. It can be administered through many routes including by mouth. This study aims to assess the use of a new route of administration in pediatric patients with epilepsy during the interictal state, and during the ictal/perictal state. The drug is approved for this population, but the new route is investigational. It is a soluble film that is placed on the inside of the mouth on the cheek. The film can be applied during a seizure, or immediately after. There have been two studies in healthy subjects to determine the amount of medication available in their blood, and one study has been done to test dose-proportionality.
Eisai Inc. E2007-G000-410
Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures. Fycompa (perampanel) is an FDA approved add-on (adjunctive) therapy for the treatment of primary generalized tonic-clonic seizures (formerly referred to as grand mal seizures). Currently, there is limited information from clinical studies regarding the use of perampanel as a first-line therapy; however, in clinical practice, doctors routinely prescribe antiepileptic drugs (AEDs) approved for add-on (adjunctive) use as a first-line therapy (monotherapy) or withdraw other drugs until the patient is only on one drug depending on their clinical response. This study looks to assess how long subjects stay on perampanel as a first-line therapy or as a first add-on therapy for either partial onset seizures or primary generalized tonic-clonic seizures.
UCB Biopharma EP0065
A multicenter, open-label study to evaluate the pharmacokinetics, safety and tolerability of intravenous BRV in subjects ≥1 month to <16 years of age with epilepsy. Epilepsy affects all races of both sexes at any age from the first hour of life to extreme old age. The prevalence of epilepsy is 1% to 2% of the population and 4% of pediatric population in those developed countries where they have been studied. The incidence of pediatric patients with Partial Onset Seizures (POS) is approximately 16 to 80 per 100,000. Within the pediatric population, the incidence is highest in children <5 years of age. The existing treatment options for POS in the pediatric population generally follow the treatment options for adults with the same disorder; clinical experience demonstrates that children may have results comparable to adults with administration of the conventional antiepileptic drugs (AEDs). More than 25% of pediatric patients have inadequate seizure control on currently available AEDs or experience significant adverse drug effects. There remains a need for potent AEDs with a positive benefit-risk profile in this population. The study drug brivaracetam (Briviact, BRV), is currently approved for the treatment of POS in ages 16 and older. The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of BRV administered as a 15-minute IV infusion and iv bolus (up to 2-minute infusion) in subjects ≥1 month to <16 years of age with epilepsy.
UCB Biopharma N01266
Open-label, single-arm, multicenter, long-term study to evaluate safety and efficacy of brivaracetam used as adjunctive treatment in pediatric subjects with epilepsy. The primary objective of this study is to provide long-term safety and tolerability data on BRV in pediatric subjects with epilepsy, while providing access to BRV for subjects who may benefit from long-term treatment.
Engage E-001 StATES
This is a double blind, placebo controlled study of STAP-001 in epilepsy patients with predictable seizure patterns (i.e., patients who can reliable predict an oncoming seizure). STAP-001 is a hand-held, single-dose, single-use drug-device combination product. Oral inhalation through the product initiates the controlled rapid heating of a thin film of alprazolam to form a thermally generated, highly pure drug vapor. The vapor condenses into aerosol particles with a particle size distribution appropriate for efficient delivery to the deep lung. The rapid absorption of the drug provides peak plasma levels in the systemic circulation within minutes after administration. This method of delivery is very different from the methods used for other benzodiazepines such as intravenous lorazepam and rectal diazepam.
A Retrospective Chart Review of Patients Less than 18 Years of Age at the Time of Implant with the RNS System Treated for Medically Intractable Epilepsy Epilepsy is a common neurologic disorder of children and adolescents. One percent of children from birth to 17 years old are diagnosed with recurrent seizures. Adolescents with medically intractable partial onset seizures are at risk for poor quality of life, including psychological symptoms, and this can be lessened with better seizure control. The responsive neurostimulator (RNS) stimulator works like a pacemaker implanted in the brain. It is currently approved by the FDA as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age and older with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antileptic medications, and currently have frequent and disabling seizures (e.g., motor partial seizures, complex partial seizures, and/or secondarily generalized seizures). The RNS system has demonstrated safety and effectiveness in patients who average 3 or more disabling seizures per month. Physicians have used the RNS system in patients younger than 18 during the course of clinical care. This study aims to use the safety and efficacy data from these patients' charts to support an expansion of the indication for use to include patients under the age of 18.
A Learning Healthcare System for Pediatric Epilepsy
The goal of this study is to create a "learning healthcare system" for pediatric epilepsy, in which clinical data are collected, analyzed, and rapidly disseminated to change practice and improve outcomes. The investigators have created a multi-centered collaborative group of pediatric epilepsy clinicians and researchers to (1) develop algorithms to identify individuals with specific sub-types of epilepsy, (2) create an active registry of children with epilepsy, (3) conduct five demonstration projects (three quality projects and two comparative effectiveness projects).
Retrospective SUDEP at Epilepsy Centers: A Case-Controlled Study
Through retrospective chart review, this study will compare cases of Sudden Unexpected Death in Epilepsy (SUDEP) against control cases to identify potential risk factors associated with SUDEP. Different epilepsy centers will participate in the study where investigators will gather information from clinical charts, EEG video and videoEEG data, brain MRI, genetic studies, EKG's and laboratory results that will allow them to identify high-risk groups. The goal of this research is to recognize patients at risk of SUDEP and start potential preventive measures that will eventually lead to greater seizure control.
RENYC: Rare Epilepsies in New York City: Epidemiology and Health Outcomes.
Improving Surveillance with Text Processing of Clinical Notes in Electronic Health Records The central idea of our proposal is that text processing of clinical notes will improve surveillance and epidemiology of the rare epilepsies. We will use the NYC-CDRN to identify affected individuals using EHRs from multiple academic medical centers. We will describe the incidence, prevalence, comorbidities, mortality, and quality of ambulatory care for these individuals. Finally, we will develop, characterize, and disseminate specifications for searching text (a set of "regular expressions") to find affected individuals in clinical notes.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Wolf during 2018 and/or 2019. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Aquestive Pharma
- BioMarin Pharmaceutical Inc.
- Gerson Lehrman Group
- greenwich pharma inc
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- BioMarin Pharmaceutical Inc.
- Eisai Inc.
- OVATION Pharmaceuticals, Inc. (Lundbeck, Inc.)
- Sunovion Pharmaceuticals Inc.
- Supernus Pharmaceuticals
- greenwich pharma inc
Scientific Advisory Board:
- Zogenix, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.